The NuROPI study is a prospective, observational, non-interventional, monocentric study conducted in the Intensive Care Unit (ICU) of Erasme Hospital, Brussels. It aims to evaluate the association between initial levels of H3.1 nucleosomes in whole blood and 30-day mortality in critically ill patients, and to validate a novel point-of-care device for nucleosome measurement against standard chemiluminescence immunoassay (ChLIA) performed on plasma.
Inclusion requires the presence of an arterial or central venous catheter for blood sampling. Exclusion criteria include age \<18, life expectancy \<24 hours, therapeutic limitations, active cancer, absence of vascular access, ICU stay \>24h before screening, or prior inclusion. Blood will be sampled at five predefined timepoints: admission (H0), 6 hours (H6), Day 1 (D1), Day 3 (D3), and Day 7 (D7). At each timepoint, four 5 mL blood tubes will be collected during routine care, and a 20 µL aliquot will be used for immediate point-of-care H3.1 measurement. Plasma will be extracted and stored for delayed ChLIA analysis. In patients with acute brain injury and an external ventricular drain (EVD), cerebrospinal fluid (CSF) will be sampled daily until Day 5, but only if the fluid is otherwise intended to be discarded. The study seeks to establish whether nucleosome levels can serve as a biomarker for prognosis and patient stratification in critical illness.
Standard ICU data such as SOFA scores and SAPS II will be recorded, as is already routinely done in some registries like Epimed.
Data will be entered into RedCap by the research team and the investigators.
The study population will consist of 130 adult critically ill patients admitted to the Intensive Care Unit (ICU) of Erasme Hospital. Eligible participants must be 18 years or older and admitted to the ICU within the past 24 hours. All patients must have arterial or central venous access for blood sampling. The population will include a diverse group of critically ill individuals representing various acute conditions commonly encountered in intensive care:
* Sepsis, as defined by SEPSIS-3 criteria (approximately 30 patients)
* Septic shock, per SEPSIS-3 (approximately 30 patients)
* Cardiogenic shock, classified as at least SCAI stage C (approximately 10 patients)
* Severe trauma, requiring at least 4 units of red blood cells within 6 hours post-admission (approximately 10 patients)
* Acute brain injury, requiring invasive neuromonitoring (approximately 20 patients)
* Post-cardiac arrest, with at least 15 minutes of no or low perfusion (approximately 20 patients)
* Severe acute pancreatitis, requiring ICU management (approximately 10 patients) This heterogeneous ICU population is specifically chosen to evaluate the relevance of H3.1 nucleosome levels across multiple critical illness etiologies.
Objectives
Primary
\- To evaluate the association between initial levels of H3.1 nucleosomes in whole blood and 30-day mortality in a cohort of critically ill patients.
Secondary
* To assess the correlation between nucleosome levels measured in whole blood at the point of care and traditional chemiluminescence immunoassays performed on plasma.
* To validate the feasibility and reliability of a novel point-of-care device for rapid nucleosome quantification.
* To determine whether nucleosome measurement is relevant across a variety of critical conditions (e.g., sepsis, septic shock, cardiogenic shock, severe trauma, cardiac arrest, acute brain injury, severe acute pancreatitis)
